Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer

Shuhei Mayanagi, Kosuke Kashiwabara, Michitaka Honda, Koji Oba, Toru Aoyama, Mitsuro Kanda, Hiromichi Maeda, Chikuma Hamada, Sotaro Sadahiro, Junichi Sakamoto, Shigetoyo Saji, Takaki Yoshikawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort.

OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection.

DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714).

SETTINGS: Individual patient data were collected from the Japanese Foundation for Multidisciplinary Treatment of Cancer clinical trials 7, 15, and 33, which evaluated the benefits of postoperative 5-fluorouracil-based adjuvant therapies in patients with locally advanced colorectal cancer.

PATIENTS: We included patients who had stage II to III colon cancer and underwent curative resection with over D2 lymph node dissection.

MAIN OUTCOME MEASURES: Main outcomes measured were risk factors for peritoneal recurrence without other organ metastasis after curative surgery.

RESULTS: Peritoneal recurrence occurred in 2.3% (86/3714) of all patients undergoing curative resection. Mean duration from operation to peritoneal recurrence was 17.0 ± 10.3 months. Of these patients with peritoneal recurrence, 29 patients (34%) had recurrence in ≥1 other organ. Multivariate analysis showed that age (≥60 y: HR = 0.531; p = 0.0182), pathological T4 (HR = 3.802; p < 0.0001), lymph node involvement (HR = 3.491; p = 0.0002), and lymphadenectomy (D2: HR = 1.801; p = 0.0356) were independent predictors of peritoneal recurrence. The overall survival was lower in patients who developed peritoneal recurrence than in those with other recurrence (HR = 1.594; p = 0.002).

LIMITATIONS: The regimens of adjuvant chemotherapy were limited to oral 5-fluorouracil.

CONCLUSIONS: Our findings clarified the risk factors for peritoneal recurrence in patients who underwent curative resection for colon cancer. See Video Abstract at http://links.lww.com/DCR/A609.

Original languageEnglish
Pages (from-to)803-808
Number of pages6
JournalDiseases of the Colon and Rectum
Volume61
Issue number7
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Colonic Neoplasms
Recurrence
Lymph Node Excision
Fluorouracil
Adjuvant Chemotherapy
Observational Studies
Colorectal Neoplasms
Multivariate Analysis
Lymph Nodes
Clinical Trials
Databases
Neoplasm Metastasis
Survival
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Mayanagi, S., Kashiwabara, K., Honda, M., Oba, K., Aoyama, T., Kanda, M., ... Yoshikawa, T. (2018). Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. Diseases of the Colon and Rectum, 61(7), 803-808. https://doi.org/10.1097/DCR.0000000000001002

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. / Mayanagi, Shuhei; Kashiwabara, Kosuke; Honda, Michitaka; Oba, Koji; Aoyama, Toru; Kanda, Mitsuro; Maeda, Hiromichi; Hamada, Chikuma; Sadahiro, Sotaro; Sakamoto, Junichi; Saji, Shigetoyo; Yoshikawa, Takaki.

In: Diseases of the Colon and Rectum, Vol. 61, No. 7, 01.07.2018, p. 803-808.

Research output: Contribution to journalArticle

Mayanagi, S, Kashiwabara, K, Honda, M, Oba, K, Aoyama, T, Kanda, M, Maeda, H, Hamada, C, Sadahiro, S, Sakamoto, J, Saji, S & Yoshikawa, T 2018, 'Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer', Diseases of the Colon and Rectum, vol. 61, no. 7, pp. 803-808. https://doi.org/10.1097/DCR.0000000000001002
Mayanagi, Shuhei ; Kashiwabara, Kosuke ; Honda, Michitaka ; Oba, Koji ; Aoyama, Toru ; Kanda, Mitsuro ; Maeda, Hiromichi ; Hamada, Chikuma ; Sadahiro, Sotaro ; Sakamoto, Junichi ; Saji, Shigetoyo ; Yoshikawa, Takaki. / Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. In: Diseases of the Colon and Rectum. 2018 ; Vol. 61, No. 7. pp. 803-808.
@article{dd1900967bc9422ebf2e8168c89b78f5,
title = "Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer",
abstract = "BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort.OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection.DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714).SETTINGS: Individual patient data were collected from the Japanese Foundation for Multidisciplinary Treatment of Cancer clinical trials 7, 15, and 33, which evaluated the benefits of postoperative 5-fluorouracil-based adjuvant therapies in patients with locally advanced colorectal cancer.PATIENTS: We included patients who had stage II to III colon cancer and underwent curative resection with over D2 lymph node dissection.MAIN OUTCOME MEASURES: Main outcomes measured were risk factors for peritoneal recurrence without other organ metastasis after curative surgery.RESULTS: Peritoneal recurrence occurred in 2.3{\%} (86/3714) of all patients undergoing curative resection. Mean duration from operation to peritoneal recurrence was 17.0 ± 10.3 months. Of these patients with peritoneal recurrence, 29 patients (34{\%}) had recurrence in ≥1 other organ. Multivariate analysis showed that age (≥60 y: HR = 0.531; p = 0.0182), pathological T4 (HR = 3.802; p < 0.0001), lymph node involvement (HR = 3.491; p = 0.0002), and lymphadenectomy (D2: HR = 1.801; p = 0.0356) were independent predictors of peritoneal recurrence. The overall survival was lower in patients who developed peritoneal recurrence than in those with other recurrence (HR = 1.594; p = 0.002).LIMITATIONS: The regimens of adjuvant chemotherapy were limited to oral 5-fluorouracil.CONCLUSIONS: Our findings clarified the risk factors for peritoneal recurrence in patients who underwent curative resection for colon cancer. See Video Abstract at http://links.lww.com/DCR/A609.",
author = "Shuhei Mayanagi and Kosuke Kashiwabara and Michitaka Honda and Koji Oba and Toru Aoyama and Mitsuro Kanda and Hiromichi Maeda and Chikuma Hamada and Sotaro Sadahiro and Junichi Sakamoto and Shigetoyo Saji and Takaki Yoshikawa",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/DCR.0000000000001002",
language = "English",
volume = "61",
pages = "803--808",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer

AU - Mayanagi, Shuhei

AU - Kashiwabara, Kosuke

AU - Honda, Michitaka

AU - Oba, Koji

AU - Aoyama, Toru

AU - Kanda, Mitsuro

AU - Maeda, Hiromichi

AU - Hamada, Chikuma

AU - Sadahiro, Sotaro

AU - Sakamoto, Junichi

AU - Saji, Shigetoyo

AU - Yoshikawa, Takaki

PY - 2018/7/1

Y1 - 2018/7/1

N2 - BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort.OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection.DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714).SETTINGS: Individual patient data were collected from the Japanese Foundation for Multidisciplinary Treatment of Cancer clinical trials 7, 15, and 33, which evaluated the benefits of postoperative 5-fluorouracil-based adjuvant therapies in patients with locally advanced colorectal cancer.PATIENTS: We included patients who had stage II to III colon cancer and underwent curative resection with over D2 lymph node dissection.MAIN OUTCOME MEASURES: Main outcomes measured were risk factors for peritoneal recurrence without other organ metastasis after curative surgery.RESULTS: Peritoneal recurrence occurred in 2.3% (86/3714) of all patients undergoing curative resection. Mean duration from operation to peritoneal recurrence was 17.0 ± 10.3 months. Of these patients with peritoneal recurrence, 29 patients (34%) had recurrence in ≥1 other organ. Multivariate analysis showed that age (≥60 y: HR = 0.531; p = 0.0182), pathological T4 (HR = 3.802; p < 0.0001), lymph node involvement (HR = 3.491; p = 0.0002), and lymphadenectomy (D2: HR = 1.801; p = 0.0356) were independent predictors of peritoneal recurrence. The overall survival was lower in patients who developed peritoneal recurrence than in those with other recurrence (HR = 1.594; p = 0.002).LIMITATIONS: The regimens of adjuvant chemotherapy were limited to oral 5-fluorouracil.CONCLUSIONS: Our findings clarified the risk factors for peritoneal recurrence in patients who underwent curative resection for colon cancer. See Video Abstract at http://links.lww.com/DCR/A609.

AB - BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort.OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection.DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714).SETTINGS: Individual patient data were collected from the Japanese Foundation for Multidisciplinary Treatment of Cancer clinical trials 7, 15, and 33, which evaluated the benefits of postoperative 5-fluorouracil-based adjuvant therapies in patients with locally advanced colorectal cancer.PATIENTS: We included patients who had stage II to III colon cancer and underwent curative resection with over D2 lymph node dissection.MAIN OUTCOME MEASURES: Main outcomes measured were risk factors for peritoneal recurrence without other organ metastasis after curative surgery.RESULTS: Peritoneal recurrence occurred in 2.3% (86/3714) of all patients undergoing curative resection. Mean duration from operation to peritoneal recurrence was 17.0 ± 10.3 months. Of these patients with peritoneal recurrence, 29 patients (34%) had recurrence in ≥1 other organ. Multivariate analysis showed that age (≥60 y: HR = 0.531; p = 0.0182), pathological T4 (HR = 3.802; p < 0.0001), lymph node involvement (HR = 3.491; p = 0.0002), and lymphadenectomy (D2: HR = 1.801; p = 0.0356) were independent predictors of peritoneal recurrence. The overall survival was lower in patients who developed peritoneal recurrence than in those with other recurrence (HR = 1.594; p = 0.002).LIMITATIONS: The regimens of adjuvant chemotherapy were limited to oral 5-fluorouracil.CONCLUSIONS: Our findings clarified the risk factors for peritoneal recurrence in patients who underwent curative resection for colon cancer. See Video Abstract at http://links.lww.com/DCR/A609.

UR - http://www.scopus.com/inward/record.url?scp=85049236356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049236356&partnerID=8YFLogxK

U2 - 10.1097/DCR.0000000000001002

DO - 10.1097/DCR.0000000000001002

M3 - Article

C2 - 29561282

AN - SCOPUS:85049236356

VL - 61

SP - 803

EP - 808

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 7

ER -